Release Date: 2024-05-28
Bladder Cancer Signs, Symptoms, and Diagnosis
Bekir Demirtas (Author), Ozgur Kazan (Author)
Release Date: 2024-05-28
This section contains information about the symptoms and diagnostic stages of bladder cancer. The approach to hematuria, the most common presenting symptom in bladder cancer, is also emphasized. The effectiveness of screening in asymptomatic patients is still debated. Traditional methods continue to be reliably used in the diagnosis of bladder cancer. However, new imaging methods [...]
Media Type
PDF
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | Current Management of Non-Muscle Invasive Bladder Cancer |
| First Page | 15 |
| Last Page | 27 |
| DOI | https://doi.org/10.69860/nobel.9786053359197.2 |
| ISBN | 978-605-335-919-7 (PDF) |
| Language | ENG |
| Page Count | 13 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Bekir Demirtas (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0002-0410-8866
3I graduated from Kocaeli University Faculty of Medicine in 2018 and currently serve as a urology resident. Throughout my career, I have contributed to both national and international publications in the field. Additionally, I have had the privilege of collaborating with esteemed professionals abroad and participating in various conferences. My experiences have enriched my understanding of urology and equipped me with valuable insights into global healthcare practices. I am passionate about advancing the field through research and clinical practice, striving to make meaningful contributions to patient care and scientific discourse.
Ozgur Kazan (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0003-0202-0454
3Huseyin Ozgur Kazan, M.D., FEBU, is a dedicated urologist specializing in urooncology, proficient in diverse surgical techniques including laparoscopic and endoscopic procedures. With a commitment to patient-centered care, he continuously enhances his expertise through ongoing professional development and clinical research. Fluent in English and German, he graduated from Ege University Faculty of Medicine and completed his residency at Istanbul Medeniyet University Faculty of Medicine Prof. Dr. Süleyman Yalçın City Hospital. His professional journey includes roles at various hospitals, including Kocaeli State Hospital and Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital. Currently, he serves as a Urology Specialist at Istanbul Medeniyet University Faculty of Medicine Prof. Dr. Süleyman Yalçın City Hospital. Notably, his research, supported by TÜBİTAK, focused on the prognostic role of PI3K and JAK/STAT pathways in regulating PDL-1 expression in prostate cancer."
1. Wéber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024 Apr 16;42(1):237.
2. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005 Dec;66(6 Suppl 1):4-34.
3. Matulewicz RS, Demzik AL, DeLancey JO, Popescu O, Makarov DV, Meeks JJ. Disparities in the diagnostic evaluation of microhematuria and implications for the detection of urologic malignancy. Urol Oncol. 2019 May;37(5):300.e1-300.e7.
4. Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 2016 May;117(5):783-6.
5. Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology. 1985 Oct;26(4 Suppl):39-46.
6. Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Comploj E et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int. 2013 Jul;112(1):68-73.
7. Tsoussis S, Ikonomidou F, Vourliotaki I, Papadaki A, Apostolakis S. Clinical burden of terminal phase in cancer patients. J BUON. 2007 Jul-Sep;12(3):383-8.
8. Button JM. Evaluation of hematuria in adults. JAMA. 1990 May 9;263(18):2475-80.
9. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int. 2006 Feb;97(2):301-5
10. Matulewicz RS, DeLancey JO, Pavey E, Schaeffer EM, Popescu O, Meeks JJ. Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. Bladder Cancer. 2017 Jan 27;3(1):45-49
11. Rao PK, Gao T, Pohl M, Jones JS. Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol. 2010 Feb;183(2):560-4.
12. Wallis CJD, Juvet T, Lee Y, Matta R, Herschorn S, Kodama R et al. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA. 2017 Oct 3;318(13):1260-1271.
13. Barocas DA, Boorjian SA, Alvarez RD, Downs TM, Gross CP, Hamilton BD et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020 Oct;204(4):778-786.
14. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19;171(3):540-556.e25.
15. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053.
16. Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013 Jun;63(6):1049-58.
17. Starke N, Singla N, Haddad A, Lotan Y. Long-term outcomes in a high-risk bladder cancer screening cohort. BJU Int. 2016 Apr;117(4):611-7.
18. Tan WS, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J et al. DETECT I Trial Collaborators. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? J Urol. 2018 Nov;200(5):973-980.
19. Wentland AL, Desser TS, Troxell ML, Kamaya A. Bladder cancer and its mimics: a sonographic pictorial review with CT/MR and histologic correlation. Abdom Radiol (NY). 2019 Dec;44(12):3827-3842.
20. Trinh TW, Glazer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol (NY). 2018 Mar;43(3):663-671.
21. Palou J, Rodríguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005 Sep;174(3):859-61; discussion 861.
22. Pecoraro M, Takeuchi M, Vargas HA, Muglia VF, Cipollari S, Catalano C et al. Overview of VI-RADS in Bladder Cancer. AJR Am J Roentgenol. 2020 Jun;214(6):1259-1268.
23. Kosaka N, Ogawa M, Choyke PL, Kobayashi H. Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol. 2009 Nov;5(9):1501-11.
24. Krajewski W, Kościelska-Kasprzak K, Rymaszewska J, Zdrojowy R. How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Qual Life Res. 2017 Mar;26(3):625-634.
25. Pearce S, Daneshmand S. Enhanced Endoscopy in Bladder Cancer. Curr Urol Rep. 2018 Aug 17;19(10):84.
26. Hsueh TY, Chiu AW. Narrow band imaging for bladder cancer. Asian J Urol. 2016 Jul;3(3):126-129.
27. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumors reduces bladder tumor recurrence due to less residual tumor tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011 Oct;108(8 Pt 2):E297-303.
28. Kamphuis GM, de Bruin DM, Brandt MJ, Knoll T, Conort P, Lapini A et al. Comparing Image Perception of Bladder Tumors in Four Different Storz Professional Image Enhancement System Modalities Using the íSPIES App. J Endourol. 2016 May;30(5):602-8.
29. Ren H, Yuan Z, Waltzer W, Shroyer K, Pan Y. Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. J Urol. 2010 Oct;184(4):1499-506.
30. Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15;121(2):169-78.
31. Palou J, Brausi M, Catto JWF. Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. Eur Urol Oncol. 2020 Aug;3(4):548-554.
32. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015 Feb;33(2):66.e25-31.
33. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019 Nov;76(5):639-657.
34. Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018 Dec;36(12):1981-1995.
35. D’Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, Shariat SF. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019 Jun;123(6):959-967.
36. Ribal MJ, Mengual L, Lozano JJ, Ingelmo-Torres M, Palou J, Rodríguez-Faba O et al.Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. Eur J Cancer. 2016 Feb;54:131-138.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
